Ozempic vs. Wegovy vs. Zepbound: which GLP-1 is right for you?
The GLP-1 conversation has gone mainstream, and with it a lot of confusion about which medication does what. Here is the breakdown, without the marketing spin.
What these medications have in common
They are all GLP-1 receptor agonists. They work by mimicking gut hormones that signal fullness, slow stomach emptying and reduce appetite. All require a prescription. Most are injectable, but that is changing fast — oral options are now available or on the immediate horizon, and they are reshaping who can access this class of medication.
Ozempic and Wegovy: same drug, different purpose
This is the most common point of confusion. Ozempic and Wegovy contain the same active ingredient, semaglutide. The difference is FDA approval and dosing. Ozempic is approved for type 2 diabetes; Wegovy is approved specifically for chronic weight management.
As of March 2026, Wegovy’s injectable range spans three doses, including a newly approved higher dose of 7.2 mg. In its trial that dose produced a mean weight loss of 20.7%, putting it in tirzepatide territory. It is intended for patients who have tolerated the 2.4 mg dose for at least four weeks and need further weight reduction. When a physician prescribes Ozempic off-label for weight loss, they are using the diabetes version.
Zepbound and Mounjaro: same story
Both contain tirzepatide. Mounjaro is approved for type 2 diabetes; Zepbound is the weight-loss branded version. Tirzepatide is a dual agonist — it activates both GLP-1 and GIP receptors, which appears to drive stronger appetite suppression and greater weight loss than semaglutide alone. Trials show average weight loss of about 21% of body weight at 72 weeks, compared with roughly 15% for standard-dose semaglutide.
The oral options
Oral semaglutide received FDA approval for weight loss in late 2025 — the first GLP-1 pill approved specifically for chronic weight management. Same active ingredient as the injection, taken once daily by mouth. For patients who are needle-averse or simply prefer a pill, this is a genuine change. Weight loss results are slightly lower than the injectable form, but for many people the trade-off in convenience is worth it.
Orforglipron is a once-daily oral GLP-1 that works differently at the molecular level, which means it does not carry the strict fasting and timing requirements oral semaglutide does. Trial results have shown meaningful weight loss comparable to injectable options, and FDA approval is anticipated by mid-2026. It may become the most accessible GLP-1 yet.
If needle aversion has been the reason you have held off, this is a good moment to revisit the conversation with a physician.
Which is more effective?
In direct comparisons, tirzepatide has consistently outperformed standard-dose semaglutide for weight loss. The new higher-dose semaglutide changes that picture — its results are directly comparable to tirzepatide’s, giving patients who have plateaued a meaningful step up within the same drug class.
“More effective on average” still does not mean one medication is right for everyone. Side effect profiles differ; the higher dose carries a higher rate of gastrointestinal side effects and a newly noted skin sensation in some patients. Cost differs. Individual responses vary significantly.
“The best GLP-1 is the one you tolerate well, can access reliably, and will actually stay on.”
Cost without insurance
At full list price, brand-name GLP-1 medications run roughly $900 to $1,300 a month. Bought through the manufacturers’ direct self-pay pharmacies, the same medications come down to roughly $349 to $549 a month. Which number applies to you depends on your coverage and the specific drug — our cost guide goes through it in detail, and your physician can tell you which route fits your prescription.
Which should you choose?
This is a clinical decision that depends on your medical history, any existing conditions — especially diabetes or thyroid history — your goals, your budget, and how your body responds. It is not a decision to make from social media trends. Your consultation reviews all of these together and settles on the right starting point for you specifically.
Yes. Oral semaglutide is now FDA-approved for weight loss and available by prescription. Orforglipron, another oral GLP-1, is expected to be approved by mid-2026 and may offer simpler dosing. Ask your physician whether an oral option suits you.
On average, yes — trials show greater weight loss with tirzepatide. But tolerability, cost and individual response all matter, and a physician should guide the decision.
Yes, switching is possible and sometimes clinically appropriate. It should be done under physician supervision with a proper plan for dosing.
All GLP-1s share a similar profile — nausea, constipation and fatigue are most common. Slow titration is the single most effective way to minimise side effects, whichever medication you use.
This article is general health information, not medical advice for your situation, and does not create a physician-patient relationship. If you are unwell, speak with a physician.
